The RESCUE trial (NCT03463876) is a phase II clinical trial exploring the safety and efficacy of Camrelizumab in combination with Apatinib (a VEGFR‐2 inhibitor) in patients with advanced HCC who have previously received Sorafenib,83 and there is also a phase I/II clinical trial (NCT04035876) currently underway in China assessing Camrelizumab and Apatinib as potential neoadjuvant therapy for downstaging/bridging of HCC prior to curative liver transplantation. This evidence concerns the gene KDR and hepatocellular carcinoma.